Biogazelle and Isis evaluate long non-coding RNAs to identify and validate novel targets for anti-cancer drugs

October 15, 2015 Leave a comment 3,070 Views

GHENT, Belgium, October 15, 2015 – Biogazelle NV today announced a research-stage collaboration with Isis Pharmaceuticals in which they will identify and validate novel targets to treat colon, liver and lung cancer, diseases with clear unmet clinical needs. As part ...

RNA-Seq Blog Transcriptome Research & Industry News

Tag Archives: Isis Pharmaceuticals

Biogazelle and Isis evaluate long non-coding RNAs to identify and validate novel targets for anti-cancer drugs

NVIGEN pioneers breakthrough in high-resolution tissue RNA sequencing with magnetic nanoparticle capture

RNA folding studies by tRNA structure-seq inside peptide-rich droplets reveal roles of modified nucleosides at the origin of life

GiRAFR – gRNA detection and annotation in single-cell CRISPR screens

RNA sequencing reaveals novel intracellular signaling mechanisms that promote melanoma growth

AAV-Perturb-seq – adeno-associated virus (AAV)-mediated direct in vivo single-cell CRISPR screening

capTEs – Cas9-assisted profiling transposable elements expression sequencing

eSPET-seq – genome-wide probing of eukaryotic nascent RNA structure